Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis

被引：1

作者：

Bonniaud, Philippe ^{[1
,2
,3
]}

Cottin, Vincent ^{[4
,5
,6
,7
]}

Spagnolo, Paolo ^{[8
,9
]}

Nolin, Maeva ^{[10
]}

Dalon, Faustine ^{[10
]}

Kirchgassler, Klaus-Uwe ^{[11
]}

Chia, Jenny ^{[12
]}

Kamath, Tripthi ^{[12
]}

Van Ganse, Eric ^{[10
,13
,14
,15
]}

Belhassen, Manon ^{[10
]}

机构：

[1] Ctr Hosp Univ Bourgogne, Ctr Reference Constitutif Malad Pulmonaires Rares, Serv Pneumol & Soins Intensifs Resp, Dijon, France

[2] Univ Bourgogne Franche Comte, Fac Med & Pharm, Dijon, France

[3] INSERM U123 1, Dijon, France

[4] Louis Pradel Hosp, Natl Reference Coordinating Ctr Rare Pulm Dis, Lyon, France

[5] Hosp Civils Lyon, F-69008 Lyon, France

[6] Univ Claude Bernard Lyon 1, Univ Lyon, UMR754, IVPC, F-69008 Lyon, France

[7] ERN LUNG, Lyon, France

[8] Univ Padua, Resp Dis Unit, Padua, Italy

[9] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy

[10] PELyon, PharmacoEpidemiol Lyon, Lyon, France

[11] F Hoffmann La Roche Ltd, Basel, Switzerland

[12] Genentech Inc, San Francisco, CA 94080 USA

[13] Croix Rousse Univ Hosp, Resp Med, Lyon, France

[14] Univ Claude Bernard Lyon 1, EA7426, Lyon, France

[15] Univ Claude Bernard Lyon 1, HESPER 7425, Hlth Serv & Performance Res, Lyon, France

来源：

关键词：

Idiopathic pulmonary fibrosis; Treatments;

D O I：

10.1183/13993003.congress-2020.1673

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

1673

引用

页数：2